08:00    Registration, Partnering Meetings, and Networking in the Exhibition Area

08:40    Welcome – Opening Remarks
Moderator: Johan Rockberg, Professor in Antibody Technology and Directed Evolution, KTH Royal Institute of Technology
Samuel Lagercrantz, Editor-in-chief, Life Science Sweden

08:45    Title Announced Shortly
Jan Holgersson, Vice Dean, Sahlgrenska Academy, and Professor of Transplantation Immunology, University of Gothenburg

09:10    The Gut Microbiome in Cardiometabolic Disease – From Correlations to Therapeutic Targets
Fredrik Bäckhed, Professor of Molecular Medicine, University of Gothenburg

09:35    Coffee, Partnering Meetings, and Networking in the Exhibition Area

10:00    Therapeutic Intervention to Slow Progression of Chronic Kidney Disease
Marie Jeansson, Associate Professor, Dept. of Medicine, Karolinska Institutet

10:25     Probing Glioblastoma Invasion Dynamics with Ex Vivo Systems and AI
Sven Nelander, Professor of Integrative Cancer Research, Uppsala University

10:50      Unlocking the Power of Biobanks: Today’s Possibilities and Tomorrow’s Needs
Hans-Christoph Paul, M.Sc. and Owner, HCP Life Science Innovation

11:05      The Evolving Landscape of Pharmacogenomics: Current Achievements and Future Direction
Magnus Ingelman-Sundberg, Senior Professor of Molecular Toxicology, Karolinska Institutet

11:30      Lunch, Partnering Meetings and Networking in the Exhibition Area

13:00      Immune Responses to SARS-CoV-2 mRNA Vaccination in Immunosuppressed Patient Populations
Hans-Gustaf Ljunggren, Professor of Infection Medicine, Karolinska Institutet

13:25      Clinically Validated Patient-Derived Organoid Platform for Drug Development
Timo Peters, Scientific Business Development Manager, HUB Organoids

13:50      Coffee, Partnering Meetings and Networking in the Exhibition Area

14:15      TAK1: A Central, Untapped Drug Target in Chronic Inflammation
Sarah Fredriksson, CEO, Aqilion

14:40      Systems Biology- & AI-Based Drug Development Targeting Mitochondrial Dysfunction in Neurodegenerative & Metabolic Diseases
Olof Nord, CEO, ScandiBio Therapeutics

15:05     To Be Announced

15:30     Concluding Remarks
Johan Rockberg, Professor in Antibody Technology and Directed Evolution, KTH Royal Institute of Technology

Approx. 15:35    End of Agenda